OSSIO, an orthopaedic surgery solutions provider, has expanded its portfolio with the launch of OSSIOfiber small compression bio-integrative staples for hand and foot procedures.
These staples are designed for use in hand and foot procedures, particularly for enhancing bunion repair through the Akin osteotomy technique.
The new product aims to improve patient satisfaction by leaving no permanent implant behind.
Approved by the US Food and Drug Administration in 2023, the OSSIOfiber small compression staples are indicated for various surgical applications in the hand and foot.
They are designed to adapt to the specific needs of each procedure, providing the necessary fixation in conjunction with appropriate brace or immobilisation.
OSSIO's Intelligent Bone Regeneration Technology is at the core of the OSSIOfiber implants, which are made from a proprietary mineral fibre matrix and a bio-friendly polymer.
This technology offers a unique solution to the limitations of permanent metal and other conventional implants.
It is engineered for rapid bone in-growth and regeneration, providing strength and facilitating natural healing.
The implants comprise bio-integrative material.
They are designed to integrate seamlessly into the patient's anatomy, promoting stability and mobility without adverse biological responses.
OSSIO's vision extends to multiple orthopaedic applications, aiming to offer OSSIOfiber implants for a wide range of surgical needs including hand and wrist, foot and ankle, upper extremity and trauma, sports medicine, paediatrics and reconstruction.
OSSIO CEO Brian Verrier said: “Our mission at OSSIO is nothing less than transforming the experience of patients who must undergo orthopaedic surgery where internal fixation is required.
“With more than 40,000 OSSIOfiber implants performed to date, just five years since commercialising our first product in 2019, we launch this new small compression staple platform, further expanding patient access to a metal-free alternative for orthopaedic fixation.”
